109 related articles for article (PubMed ID: 38832281)
1. Real-world drug treatment models of novel targeted drugs in Chinese patients with gynecological cancer from 2017 to 2021: A cross-sectional analysis.
Li C; Jin J; Tang J
Heliyon; 2024 Jun; 10(11):e31371. PubMed ID: 38832281
[TBL] [Abstract][Full Text] [Related]
2. Real world drug treatment models for pregnancy complicated with urinary tract infection in China from 2018 to 2022: a cross-section analysis.
Jin J; Li C; He Y; Pan J; Zhu J; Tang J
Front Pharmacol; 2024; 15():1349121. PubMed ID: 38348394
[No Abstract] [Full Text] [Related]
3. Real-world prescription patterns for reproductive assistance patients in China: A trend analysis from 2016 to 2020.
Jin J; Zhu J; Tang J
Front Pharmacol; 2022; 13():1021150. PubMed ID: 36467066
[No Abstract] [Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
7. Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.
Carreras MJ; Tomás-Guillén E; Farriols A; Renedo-Miró B; Valdivia C; Vidal J; Saura C; Carles J; Felip E; Gorgas MQ; Tabernero J; Monterde J
Curr Oncol; 2023 Aug; 30(9):7984-8004. PubMed ID: 37754495
[TBL] [Abstract][Full Text] [Related]
8. Real-world pharmacological treatment patterns of patients with threatened miscarriage in China from 2014 to 2020: A cross-sectional analysis.
Pang YY; Ma CL
J Clin Pharm Ther; 2022 Feb; 47(2):228-236. PubMed ID: 34704273
[TBL] [Abstract][Full Text] [Related]
9. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of prescription and rationality of anti-hypertensive medication among community health centers in Beijing].
Bai JJ; Zhang WL; Wang L; Liu PY; Cai J
Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Oct; 49(10):993-999. PubMed ID: 34674437
[No Abstract] [Full Text] [Related]
11. Real-world pharmacological treatment of patients with postpartum depression in China from 2016 to 2020: A cross-sectional analysis.
Sun K; Wang X
Saudi Pharm J; 2022 Oct; 30(10):1418-1425. PubMed ID: 36387336
[TBL] [Abstract][Full Text] [Related]
12. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
Arend RC; O'Malley DM; Banerjee S; McLaurin K; Davidson R; Long GH
Adv Ther; 2022 Jan; 39(1):328-345. PubMed ID: 34727316
[TBL] [Abstract][Full Text] [Related]
13. Cost of pain medication to treat adult patients with nonmalignant chronic pain in the United States.
Rasu RS; Vouthy K; Crowl AN; Stegeman AE; Fikru B; Bawa WA; Knell ME
J Manag Care Spec Pharm; 2014 Sep; 20(9):921-8. PubMed ID: 25166291
[TBL] [Abstract][Full Text] [Related]
14. Olaparib and niraparib as maintenance therapy in patients with newly diagnosed and platinum-sensitive recurrent ovarian cancer: A single-center study in China.
Wang D; Shi X; Pei J; Zhang C; Peng L; Zhang J; Zheng J; Peng C; Huang X; Liu X; Liu H; Zhang G
Chin Med J (Engl); 2024 Apr; ():. PubMed ID: 38679485
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
[TBL] [Abstract][Full Text] [Related]
16. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
Harrison RF; Fu S; Sun CC; Zhao H; Lu KH; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2021 Jul; 225(1):68.e1-68.e11. PubMed ID: 33549538
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
Zhong L; Tran AT; Tomasino T; Nugent E; Smith JA
J Manag Care Spec Pharm; 2018 Dec; 24(12):1219-1228. PubMed ID: 30479195
[TBL] [Abstract][Full Text] [Related]
18. A Real World Perspective of PARP Inhibitor Use in Gynecological Cancer Patients.
Lee CS; Hernandez J; Liang C; Leung A; Stefanov DG; Cheng K; John V
J Pharm Pract; 2023 Oct; 36(5):1134-1141. PubMed ID: 35439094
[No Abstract] [Full Text] [Related]
19. [Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].
He Y; Wang Y; Ji C; Liu Y; Wu YM
Zhonghua Fu Chan Ke Za Zhi; 2022 May; 57(5):352-360. PubMed ID: 35658326
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
